RecallRadar

FDA Drug recall D-0090-2023

Ganciclovir for Injection, USP, 500mg per vial, packaged in a 10-count carton, Rx Only, Mfd. by: THYMOORGAN PHARMAZIE GmbH, Germany, Distri…

On 2023-01-04 the FDA classified a Class II recall of Ganciclovir for Injection, USP, 500mg per vial, packaged in a 10-count carton, Rx Only, Mfd. by: THYMOORGAN PHARMAZIE GmbH, Germany, Distri… by Hikma Pharmaceuticals Usa, citing labeling: Label mix-up - one vial was mislabeled as Cladribine Injection 10mg/mL inside a 10-count carton of Ganciclovir 500 mg.

Read the official FDA Drug notice

AgencyFDA Drug
Recall numberD-0090-2023
ClassificationClass II
Statusterminated
Initiated2022-12-16
Published2023-01-04
Last updated2026-09-13 11:52 UTC
CompanyHikma Pharmaceuticals Usa
DistributionUS

Product

Ganciclovir for Injection, USP, 500mg per vial, packaged in a 10-count carton, Rx Only, Mfd. by: THYMOORGAN PHARMAZIE GmbH, Germany, Distributed by Hikma Berkeley Heights, NJ 07922, NDC 0143-9299-01

Reason

Labeling: Label mix-up - one vial was mislabeled as Cladribine Injection 10mg/mL inside a 10-count carton of Ganciclovir 500 mg.

Identifiers

ndc0143-9299-01
ndc0143-9299-10
code_infoLot#: BQ0006, Exp 08/2023

Status history

No status changes recorded since RecallRadar first saw this recall on 2026-09-13 11:52 UTC. Current status: terminated.

Source

Official record: https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0090-2023%22

RecallRadar indexes public recall notices from the FDA, USDA FSIS, and CPSC. The official agency notice is the authoritative source. Always confirm details at the linked source before acting.